Journal Mobile Options
Table of Contents
Vol. 51, No. 3, 2008
Issue release date: September 2008
Section title: Original Paper
Intervirology 2008;51:173–181
(DOI:10.1159/000151530)

Development of Human Single-Chain Antibodies against SARS-Associated Coronavirus

Leung K.M. · Feng D.X. · Lou J. · Zhou Y. · Fung K.P. · Waye M.M.Y. · Tsui S.K.W. · Chan P.K.S. · Marks J.D. · Pang S.F. · Kan Y.W.
aCK Life Sciences International Inc., Hong Kong, SAR, China; bDepartment of Laboratory Medicine, University of California, San Francisco, Calif., USA; cDepartment of Biochemistry, Croucher Laboratory for Human Genomics, and dDepartment of Microbiology, Chinese University of Hong Kong, Hong Kong, SAR, China; eDepartment of Anesthesia and Pharmaceutical Chemistry, University of California, San Francisco General Hospital, San Francisco, Calif., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 1/30/2008
Accepted: 8/5/2008
Published online: 8/25/2008

Number of Print Pages: 9
Number of Figures: 7
Number of Tables: 2

ISSN: 0300-5526 (Print)
eISSN: 1423-0100 (Online)

For additional information: http://www.karger.com/INT

Abstract

The outbreak of severe acute respiratory syndrome (SARS), caused by a distinct coronavirus, in 2003 greatly threatened public health in China, Southeast Asia as well as North America. Over 1,000 patients died of the SARS virus, representing 10% of infected people. Like other coronaviruses, the SARS virus also utilizes a surface glycoprotein, namely the spike protein, to infect host cells. The spike protein of SARS virus consists of 1,255 amino acid residues and can be divided into two sub-domains, S1 and S2. The S1 domain mediates the binding of the virus to its receptor angiotensin-converting enzyme 2, which is abundantly distributed on the surface of human lung cells. The S2 domain mediates membrane fusion between the virus and the host cell. Hence two strategies can be used to block the infection of the SARS virus, either by interfering with the binding of the S1 domain to the receptor or by blocking the fusion of the virus with the cell membrane mediated by the S2 domain. Several antibodies against the S1 domain have been generated and all of them are able to neutralize the virus in vitro and in vivo using animal models. Unfortunately, point mutations have been identified in the S1 domain, so that the virus isolated in the future may not be recognized by these antibodies. As no mutation has been found in the S2 domain indicating that this region is more conserved than the S1 domain, it may be a better target for antibody binding. After predicting the immunogenicity of the epitopes of the S2 domain, we chemically synthesized two peptides and also expressed one of them using a recombinant DNA method. We screened a phage displaying library of human single-chain antibodies (ScFv) against the predicted epitopes and obtained a human ScFv which can recognize the SARS virus in vitro.


  

Author Contacts

K.M. Leung
Room 610, Mong Man Wai Building
Department of Biochemistry, Chinese University of Hong Kong
Hong Kong, SAR (China)
Tel. +852 9420 4960, Fax +852 2651 9324, E-Mail karmanlg@hotmail.com

  

Article Information

Received: January 30, 2008
Accepted after revision: May 8, 2008
Published online: August 25, 2008
Number of Print Pages : 9
Number of Figures : 7, Number of Tables : 2, Number of References : 19

  

Publication Details

Intervirology (International Journal of Basic and Medical Virology)

Vol. 51, No. 3, Year 2008 (Cover Date: September 2008)

Journal Editor: Liebert U.G. (Leipzig)
ISSN: 0300–5526 (Print), eISSN: 1423–0100 (Online)

For additional information: http://www.karger.com/INT


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 1/30/2008
Accepted: 8/5/2008
Published online: 8/25/2008

Number of Print Pages: 9
Number of Figures: 7
Number of Tables: 2

ISSN: 0300-5526 (Print)
eISSN: 1423-0100 (Online)

For additional information: http://www.karger.com/INT


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.